AHA 22: SPYRAL HTN-ON MED: Renal Denervation in Patients with Hypertension | Dr David Kandzari

Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
In this insightful interview, Dr David Kandzari (Piedmont Heart Institute, Atlanta, US) joins us to outline the 6-month primary findings of an extension study of the SPYRAL HTN-ON MED Trial (NCT02439775).
SPYRAL HTN aimed to determine the safety and effectiveness of Symplicity Spyral™ multi-electrode renal denervation system (Medtronic) in patients with hypertension and cardiovascular diseases as compared to a sham procedure. This extension trial aims to determine the long-term outcomes of this trial.
This trial demonstrated that despite a significant reduction in Office BP and Win Ratio favoring RDN vs Sham, the primary efficacy endpoint was not met for 24-hr ABPM at 6 months.
Recorded remotely from Atlanta, 2022.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

[@MikaelVitally-rf5pn]

High blood pressure is the symptom for a medical problem. Artificially lowering blood pressure with drugs does not treat the "root cause" .While medication can control blood pressure, it cannot cure the condition.